Aditya Kohli - Phathom Pharmaceuticals CoFounder

PHAT Stock

USD 9.09 0.25 2.68%

Insider

Aditya Kohli is CoFounder of Phathom Pharmaceuticals

Age	36
Address	100 Campus Drive, Florham Park, NJ, United States, 07932
Phone	877 742 8466
Web	https://www.phathompharma.com

Aditya Kohli Latest Insider Activity

Tracking and analyzing the buying and selling activities of Aditya Kohli against Phathom Pharmaceuticals stock is an integral part of due diligence when investing in Phathom Pharmaceuticals. Aditya Kohli insider activity provides valuable insight into whether Phathom Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Phathom Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phathom Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

		Aditya Kohli over a month ago Disposition of 8866 shares by Aditya Kohli of Hillevax at 14.9315 subject to Rule 16b-3
		Aditya Kohli over six months ago Disposition of 6000 shares by Aditya Kohli of Hillevax at 14.205 subject to Rule 16b-3
		Aditya Kohli over six months ago Disposition of 6000 shares by Aditya Kohli of Hillevax at 15.4482 subject to Rule 16b-3
		Aditya Kohli over six months ago Disposition of 723 shares by Aditya Kohli of Hillevax at 14.1542 subject to Rule 16b-3

Phathom Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.5767) % which means that it has lost $0.5767 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 2.91 in 2024, whereas Return On Tangible Assets are likely to drop (0.51) in 2024. At this time, Phathom Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 325 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 26.7 M in 2024.

Compare Phathom Pharmaceuticals to Peers

Predict price of Phathom Pharmaceuticals

Phathom Pharmaceuticals currently holds 139.03 M in liabilities with Debt to Equity (D/E) ratio of 2.43, implying the company greatly relies on financing operations through barrowing. Phathom Pharmaceuticals has a current ratio of 9.73, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Phathom Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Eric MD	Acumen Pharmaceuticals	69
	Waldemar Priebe	Cns Pharmaceuticals	N/A
	DSc MSE	Immix Biopharma	75
	Debra Canner	Amylyx Pharmaceuticals	65
	Jenna Cohen	Blueprint Medicines Corp	N/A
	Gabriel BA	Immix Biopharma	37
	Kerry MD	Terns Pharmaceuticals	N/A
	Steve Andre	Cullinan Oncology LLC	N/A
	Mark Vignola	Terns Pharmaceuticals	46
	Murray MD	X4 Pharmaceuticals	63
	Donald MBA	Lyra Therapeutics	70
	MBA MBA	Inozyme Pharma	65
	Launa Aspeslet	Hepion Pharmaceuticals	N/A
	Dr MBA	Blueprint Medicines Corp	54
	MBA MD	Immix Biopharma	49
	Janice Hitchcock	Acumen Pharmaceuticals	N/A
	MD MBA	Amylyx Pharmaceuticals	63
	Stefan Riley	Inozyme Pharma	N/A
	Siew MS	Acumen Pharmaceuticals	N/A
	Margaret MBA	Amylyx Pharmaceuticals	59
	Charles II	Day One Biopharmaceuticals	47

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. Phathom Pharmaceuticals (PHAT) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Florham Park, NJ, United States, 07932 and employs 452 people. Phathom Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

	Return On Equity	-34.89
	Return On Asset	-0.58

Phathom Pharmaceuticals Leadership Team

Elected by the shareholders, the Phathom Pharmaceuticals' board of directors comprises two types of representatives: Phathom Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phathom. The board's role is to monitor Phathom Pharmaceuticals' management team and ensure that shareholders' interests are well served. Phathom Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phathom Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Anthony Guzzo, Chief Officer
	Joseph JD, Chief Officer
	Tom Harris, Chief Officer
	Terrie Curran, CEO President
	Martin Gilligan, Chief Officer
	JD Esq, General Secretary
	David Socks, CoFounder Director
	Aditya Kohli, CoFounder
	Eckhard MD, Chief Officer
	Paul Cocja, Chief Officer
	MPH MD, CoFounder COO

Phathom Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phathom Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-34.89
	Return On Asset	-0.58
	Operating Margin	(4.33) %
	Current Valuation	480.38 M
	Shares Outstanding	68.38 M
	Shares Owned By Insiders	7.69 %
	Shares Owned By Institutions	92.31 %
	Number Of Shares Shorted	17.45 M
	Price To Book	25.37 X
	Price To Sales	24.31 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC